Biologicznie aktywne związki chromu (III) i ich znaczenie w żywieniu człowieka i farmakoterapii

• Autorzy: Krejpcio Z. , Szymusiak H. , Wojciak R. W. , Zielinski R.

Warianty tytułu

EN

Biologically active chromium (III) compounds and their significance in human nutrition and pharmacotherapy

• Języki publikacji: PL

Abstrakty

PL

W pracy przedstawiono poglądy na temat biologicznego znaczenia chromu (III), zwrócono uwagę na nowe hioaktywne związki chromu oraz możliwość ich wykorzystania w suplementach dietetycznych oraz farmakoterapii.

EN

This article is a review of current opinions on biological significance of chromium (HI) for human and animal organisms, attention has been paid on new bioactive chromium compounds and possibilities of their application in dietary supplements and pharmaceuticals.

• Wydawca: -
• Czasopismo: Żywienie Człowieka i Metabolizm. Suplement
• Rocznik: 2005
• Tom: 32
• Numer: 1 cz.1
• Opis fizyczny: s.495-498,rys.,bibliogr.

Twórcy

autor

Krejpcio Z.

• Katedra Higieny Żywienia Człowieka, Akademia Rolnicza im.Augusta Cieszkowskiego w Poznaniu, Poznań

autor

Szymusiak H.

autor

Wojciak R. W.

autor

Zielinski R.

Bibliografia

• 1. Anderson R.A.: Chromium, glucose intolerance and diabetes. J. Am. Coll. Nutr. 1998, 17, 6, 548-555.
• 2. Anderson R.A., Polansky M.M., Bryden N.A., Petterson K.Y., Veillon C, Glinsmann R.: Effect of chromium supplementation on urinary Cr excretion of human subjects and correlation of Cr excretion with selected clinical parameters. J. Nutr. 1983, 113, 276-281.
• 3. Cheng N., Zhu X., Shi H., Chi J., Yang W., Cheng J., Bryden N.A., Anderson R.A.: Chromium supplementation of people with type 2 diabetes in China. A follow-up study. Abstract book, Dedham, MA, 1998, May 1-2, 5.
• 4. Clodfelder B.J., Chang C, Vincent J.B.: Absorption of the biomimetic chromium cation triaqua-µ3-oxo-µ-hexapropionatotrichromium (III) in rats. Biol. Trace Elem. Res. 2004, 97, 1-11.
• 5. Clodfelder J., Gullick B.M., Lukaski H.C., Neggers Y., Vincent J.B.: Oral administration of the biomimetic [Cr3O(O2CCH2CH3)6(H2O)3]+ increases insulin sensitivity and improved blood plasma variables in healtrhy and type 2 diabetic rats. J. Biol. Inorg. Chem., 2005, 10, 119-130.
• 6. Davis C.M., Vincent J.B.: Isolation and characterization of a biologically active form of chromium oligopeptide from bovine liver. Arch. Biochem. 1997, 339, 335-343.
• 7. Directive 2002/46/EC on the approximation of the law state the member states relating to food supplements.
• 8. Evans G.N., Bowman T.D.: Chromium picolinate increases membrane fluidity and rate of insulin internalization. J. Inorg. Biochem. 1992, 46, 243.
• 9. Evans, G.W., U.S. patent No. 4.315.927 Chem. Abstr. 1981, 95, 23384.
• 10. Harton A., Terrell K., Hoffman J.C.: Synthesis and characterization of novel oxo-bridged dinuclear and hydroxo-bridged trinuclear chromium (III) assembles. Inorg. Chem. 1997, 36,4875-4882.
• 11. Hepburn D.D.D., Burney J.M., Woski S.A., Vincent J.B.: The nutritional supplement chromium picolinate generates oxidative DNA damage and peroxidized lipids in vitro. Polyhedron, 203, 22, 455-463.
• 12. Levina A., Codd R., Dillon C.T., Lay P.A.: Chromium in biology: Toxicology and nutritional aspects, w: Progress in inorganic chemistry, 2002, vol. 51, 214-220. Eds. Kenneth D., Karlin.
• 13. Offenbacher E., Pi- Sunyer F.X.: Beneficial effect of chromium-rich yeast on glucose tolerance an blood lipids in elderly subjects. Diabetes, 1980, 29, 919-925.
• 14. Press R.I., Geller J.: The effect of chromium picolinate on serum cholesterol and apolipoprotein fraction in human subjects. West J. Med. 1990, 152, 41-45.
• 15. Schwarz K., Mertz W.: Chromium (III) and the glucose tolerance factor. Arch. Bioch. Biophys. 1959, 85, 292-295.
• 16. Shute A.A., Vincent J.B. The fate of the biomimetic cation triaqua-µ-oxohexapropionatetrichromium (III) in rats. J. Inorg. Chem., 2002, 272-278.
• 17. Speetjens J.K., Collins R.A., Vincent J.B., Woski S.A.: The nutritional supplement chromium (III) tris(picolinate) cleaves DNA. Chem. Res. Toxicol. 1999, 12, 483-487.
• 18. Speetjens J.K., Parand A., Crowder M.W., Vincent J.B.: Low-molecular-weight, chromium-binding substance and biomimetic [Cr3O(O2CCH2CH3)6(H2O)3]+ do not cleave DNA under physiologically relevant conditions. Polyhedron, 1999, 18, 2617-2624.
• 19. Steams D.M., Wise J.P. Patierno S.R., Wetterhahn K.E.: Chromium(III) picolinate produces chromosome damage in Chinese hamster ovary cells. FASEB J. 1995, 1643-1648.
• 20.Vincent J.B.: Quest for the molecular mechanism of chromium action and its relationship to diabetes. Nutr. Rev. 2000, 58, 3, 67-72.
• 21 .Vincent J.B.: Mechanisms of chromium action: low-molecular-weight, chromium-binding substance. J. Am. Coll. Nutr. 1999, 18, 6-12.
• 22. Vincent J.B.: The biomimetic chemistry of chromium (III). Polyhedron, 2001, 20, 1-26.
• 23. Wada O., Wu G.Y., Yamamoto A., Manabe S., Ono T.: Purification and chromium- excretory function of low-molecular-weigh, chromium-binding substance from dog liver. Environ. Res. 1983, 32, 228-239.
• 24. Yamamoto A., Wada O., Manabe S.: Evidence that chromium is an essential factor for biological activity of low-molecular-weight, chromium-binding substance. Biochem. Biophys.Res. Commun. 1989, 163, 189-193.
• 25. Yamamoto A., Wada O., Suzuki H.: Purification and properties of biologically active chromium complex from bovine Colostrums. J. Nutr. 1988, 118, 39-45.